TY - JOUR
T1 - The effects of different periods of co-administration of oral and long-acting injectable aripiprazole
T2 - A propensity score analysis
AU - Hatano, Masakazu
AU - Kamei, Hiroyuki
AU - Takeuchi, Ippei
AU - Tozawa, Kaori
AU - Makino, Shinya
AU - Hanya, Manako
AU - Yamada, Shigeki
AU - Iwata, Nakao
N1 - Publisher Copyright:
© 2018 John Wiley & Sons, Ltd.
PY - 2019/1
Y1 - 2019/1
N2 - Objective: Long-acting injectable (LAI) aripiprazole is recommended to be combined with oral aripiprazole for 2 weeks after its introduction. However, we often experience patients who require more than 2 weeks of combined use. Therefore, differences in combination periods need to be examined. Methods: This was a case–control study. We surveyed prescription profiles for oral aripiprazole administration in conjunction with LAI aripiprazole introduction and assessed the clinical course during a 12-week follow-up period. Results: Among 121 patients, 58 (47.9%) were administered both oral and LAI aripiprazole for more than 2 weeks. Although there was no significant difference in treatment failure (defined as psychiatric hospitalization or discontinuation of LAI aripiprazole from any cause) between the two groups, the group that was administered oral aripiprazole for more than 2 weeks received less additional benzodiazepines compared with that of the 2 weeks group (adjusted odds ratio, 0.055; 95% confidence interval [0.0060, 0.50]; p < 0.01). Conclusions: Our data support a flexible co-administration period for oral and LAI aripiprazole in consideration of the pharmacokinetics, but further studies are needed.
AB - Objective: Long-acting injectable (LAI) aripiprazole is recommended to be combined with oral aripiprazole for 2 weeks after its introduction. However, we often experience patients who require more than 2 weeks of combined use. Therefore, differences in combination periods need to be examined. Methods: This was a case–control study. We surveyed prescription profiles for oral aripiprazole administration in conjunction with LAI aripiprazole introduction and assessed the clinical course during a 12-week follow-up period. Results: Among 121 patients, 58 (47.9%) were administered both oral and LAI aripiprazole for more than 2 weeks. Although there was no significant difference in treatment failure (defined as psychiatric hospitalization or discontinuation of LAI aripiprazole from any cause) between the two groups, the group that was administered oral aripiprazole for more than 2 weeks received less additional benzodiazepines compared with that of the 2 weeks group (adjusted odds ratio, 0.055; 95% confidence interval [0.0060, 0.50]; p < 0.01). Conclusions: Our data support a flexible co-administration period for oral and LAI aripiprazole in consideration of the pharmacokinetics, but further studies are needed.
UR - http://www.scopus.com/inward/record.url?scp=85057300555&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=85057300555&partnerID=8YFLogxK
U2 - 10.1002/hup.2681
DO - 10.1002/hup.2681
M3 - Article
C2 - 30480343
AN - SCOPUS:85057300555
SN - 0885-6222
VL - 34
JO - Human Psychopharmacology
JF - Human Psychopharmacology
IS - 1
M1 - e2681
ER -